In order to prevent serious disease, COVID-19 patients are administered the antiviral medication paxlovid, which will soon become considerably more expensive to procure.
Pfizer has revised the cost of a five-day course of therapy to $1,390 when the medicine enters the commercial market. This is more than double the $529 that the federal government had previously paid for the treatment.
The Wall Street Journal was able to access a letter that Pfizer issued to pharmacies on October 18, in which the company disclosed the increased prices.